SCHEMBL2191190

SCHEMBL2191190

ON=C(Nc1ccc(F)c(Cl)c1)c1cc(-c2ccco2)on1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 11/20 0.76
MEN1 O00255 9/20 0.76
POLB P06746 1/20 0.54
ALDH1A1 P00352 7/20 0.50
HSD17B10 Q99714 5/20 0.50
KDM4E B2RXH2 3/20 0.50
HPGD P15428 3/20 0.50
PLA2G1B P04054 1/20 0.50
ATG4B Q9Y4P1 1/20 0.50
GAA P10253 1/20 0.49
KLK7 P49862 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
RAB9A P51151 2/20 0.46
ALOX15 P16050 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
MAPT P10636 3/20 0.44
MAPK1 P28482 1/20 0.44
HTT P42858 1/20 0.44
TSHR P16473 1/20 0.44
NPC1 O15118 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2191186 1.00 KMT2A (0.76) KMT2AMEN1POLBALDH1A1HSD17B10
SCHEMBL17318514 0.86 KMT2A (1.00) KMT2AMEN1POLBALDH1A1HSD17B10
SCHEMBL12507025 0.85 KMT2A (0.77) KMT2AMEN1POLBALDH1A1HSD17B10
SCHEMBL2191268 0.84 MEN1 (0.53) KMT2AMEN1ALDH1A1GAAL3MBTL1
SCHEMBL2191264 0.84 MEN1 (0.53) KMT2AMEN1ALDH1A1GAAL3MBTL1
SCHEMBL2192627 0.79 KMT2A (0.51) KMT2AMEN1ALDH1A1KDM4EL3MBTL1
SCHEMBL2192621 0.79 KMT2A (0.51) KMT2AMEN1ALDH1A1KDM4EL3MBTL1
SCHEMBL2191191 0.79 KMT2A (0.58) KMT2AMEN1POLBALDH1A1HSD17B10
SCHEMBL2190712 0.78 L3MBTL1 (0.62) KMT2AMEN1ALDH1A1GAAL3MBTL1
SCHEMBL2190710 0.78 L3MBTL1 (0.62) KMT2AMEN1ALDH1A1GAAL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2064207-B1 N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase INCYTE CORP (US) 2013-11-06 EP claimed
US-8377976-B2 N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase INCYTE CORPORATION (US) 2013-02-19 US claimed
US-20110172279-A1 N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE INCYTE CORPORATION, A DELAWARE CORPORATION 2011-07-14 US claimed
EP-2064207-A2 N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE Incyte Corporation (US) 2009-06-03 EP claimed
US-20080125470-A1 N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE INCYTE CORPORATION (US) 2008-05-29 US claimed
WO-2008036642-A2 N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE INCYTE CORPORATION (US) 2008-03-27 WO claimed
EP-2064207-B1 N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase INCYTE CORP (US) 2013-11-06 EP disclosed
US-8377976-B2 N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase INCYTE CORPORATION (US) 2013-02-19 US disclosed
US-8377976-B2 N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase INCYTE CORPORATION (US) 2013-02-19 US disclosed
US-20110172279-A1 N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE INCYTE CORPORATION, A DELAWARE CORPORATION 2011-07-14 US disclosed
US-20110172279-A1 N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE INCYTE CORPORATION, A DELAWARE CORPORATION 2011-07-14 US disclosed
US-20080125470-A1 N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE INCYTE CORPORATION (US) 2008-05-29 US disclosed
US-20080125470-A1 N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE INCYTE CORPORATION (US) 2008-05-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172279-A1 N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE IDO1, IDO2, HNMT KMT2A 675/4885MEN1 2391/4885POLB 3968/4885
US-20080125470-A1 N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE IDO1, IDO2, HNMT KMT2A 675/4885MEN1 2391/4885POLB 3968/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.